News Related to MTAP Deleted

Related coverage linked through entity extraction aliases.

Tango Therapeutics plans pivotal vopimetostat trial in second-line pancreatic cancer

Apr 19, 2026

Tango Therapeutics said it plans to start a pivotal 300-patient randomized vopimetostat trial in second-line pancreatic cancer this year after FDA interactions. The company also reported early combination enrollment with daraxonrasib and zoldonrasib and said more monotherapy and combination data are expected later this year.

Two Biotech Companies Report 2025 Financial Results and Pipeline Progress

Feb 26, 2026

Edgewise Therapeutics and IDEAYA Biosciences released annual financial reports detailing clinical trial progress and strategic initiatives. Both companies are advancing multiple clinical-stage programs while managing significant operating expenses.